-
1
-
-
79251490374
-
New driver mutations in non-small-cell lung cancer
-
Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011;12(2):175-180.
-
(2011)
Lancet Oncol
, vol.12
, Issue.2
, pp. 175-180
-
-
Pao, W.1
Girard, N.2
-
2
-
-
34547638047
-
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
-
Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153): 561-566.
-
(2007)
Nature
, vol.448
, Issue.7153
, pp. 561-566
-
-
Soda, M.1
Choi, Y.L.2
Enomoto, M.3
-
3
-
-
36849065315
-
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
-
Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131(6):1190- 1203.
-
(2007)
Cell
, vol.131
, Issue.6
, pp. 1190-1203
-
-
Rikova, K.1
Guo, A.2
Zeng, Q.3
-
4
-
-
84856877692
-
The potential for crizotinib in non-small cell lung cancer: A perspective review
-
Bang YJ. The potential for crizotinib in non-small cell lung cancer: a perspective review. Ther Adv Med Oncol. 2011;3(6):279-291.
-
(2011)
Ther Adv Med Oncol
, vol.3
, Issue.6
, pp. 279-291
-
-
Bang, Y.J.1
-
5
-
-
78049425319
-
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
-
Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693- 1703.
-
(2010)
N Engl J Med
, vol.363
, Issue.18
, pp. 1693-1703
-
-
Kwak, E.L.1
Bang, Y.J.2
Camidge, D.R.3
-
6
-
-
70349336416
-
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK
-
Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27(26):4247-4253.
-
(2009)
J Clin Oncol
, vol.27
, Issue.26
, pp. 4247-4253
-
-
Shaw, A.T.1
Yeap, B.Y.2
Mino-Kenudson, M.3
-
7
-
-
69349083935
-
Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population
-
Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009;15(16):5216-5223.
-
(2009)
Clin Cancer Res
, vol.15
, Issue.16
, pp. 5216-5223
-
-
Rodig, S.J.1
Mino-Kenudson, M.2
Dacic, S.3
-
8
-
-
77649091118
-
A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry
-
Mino-Kenudson M, Chirieac LR, Law K, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res. 2010;16(5):1561-1571.
-
(2010)
Clin Cancer Res
, vol.16
, Issue.5
, pp. 1561-1571
-
-
Mino-Kenudson, M.1
Chirieac, L.R.2
Law, K.3
-
10
-
-
77958072139
-
The tissue is the issue: Personalized medicine for non-small cell lung cancer
-
Hirsch FR, Wynes MW, Gandara DR, Bunn PA Jr. The tissue is the issue: personalized medicine for non-small cell lung cancer. Clin Cancer Res. 2010; 16(20):4909-4911.
-
(2010)
Clin Cancer Res
, vol.16
, Issue.20
, pp. 4909-4911
-
-
Hirsch, F.R.1
Wynes, M.W.2
Gandara, D.R.3
Bunn Jr., P.A.4
-
11
-
-
37549059613
-
Cytoreductive antitumor activity of PF-2341066, A novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
-
Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 2007; 6(12, pt 1):3314-3322.
-
(2007)
Mol Cancer Ther
, vol.6
, Issue.12 PART 1
, pp. 3314-3322
-
-
Christensen, J.G.1
Zou, H.Y.2
Arango, M.E.3
-
12
-
-
34249324494
-
An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms
-
Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007;67(9):4408-4417.
-
(2007)
Cancer Res
, vol.67
, Issue.9
, pp. 4408-4417
-
-
Zou, H.Y.1
Li, Q.2
Lee, J.H.3
-
13
-
-
77955174967
-
Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC) [abstract 3]
-
Bang Y, Kwak EL, Shaw AT, et al. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC) [abstract 3]. J Clin Oncol. 2010;28(suppl):18s.
-
(2010)
J Clin Oncol
, vol.28
, Issue.SUPPL.
-
-
Bang, Y.1
Kwak, E.L.2
Shaw, A.T.3
-
14
-
-
80052492099
-
Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC) [abstract 2501]
-
Camidge DR, Bang Y, Kwak EL, et al. Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC) [abstract 2501]. J Clin Oncol. 2011;29(suppl):165s.
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL.
-
-
Camidge, D.R.1
Bang, Y.2
Kwak, E.L.3
-
15
-
-
80051780280
-
Initial phase 2 results with crizotinib inadvanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005 [abstract 7514]
-
Crinò L, Kim D-W, Riely G, et al. Initial phase 2 results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005 [abstract 7514]. J Clin Oncol. 2011;29(suppl):479s.
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL.
-
-
Crinò, L.1
Kim, D.-W.2
Riely, G.3
-
16
-
-
84870894199
-
-
Accessed October, 7, 2011
-
Xalkori prescribing information. http://www.accessdata.fda.gov/ drugsatfda-docs/label/2011/202570s000lbl.pdf. Accessed October 7, 2011
-
Xalkori prescribing information
-
-
-
17
-
-
2442661845
-
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
-
Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22(9):1589-1597.
-
(2004)
J Clin Oncol
, vol.22
, Issue.9
, pp. 1589-1597
-
-
Hanna, N.1
Shepherd, F.A.2
Fossella, F.V.3
-
18
-
-
22044445517
-
Erlotinib in previously treated non-small-cell lung cancer
-
Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123-132.
-
(2005)
N Engl J Med
, vol.353
, Issue.2
, pp. 123-132
-
-
Shepherd, F.A.1
Rodrigues, P.J.2
Ciuleanu, T.3
-
19
-
-
84864432794
-
Correlations between the percentage of tumor cells showing an ALK (anaplastic lymphoma kinase) Gene rearrangement, ALK Signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization- positive nonsmall cell lung Cancer
-
[published online ahead of print January], doi:10.1002/cncr. 27411
-
Camidge DR, Theodoro M, Maxson DA, et al. Correlations between the percentage of tumor cells showing an ALK (anaplastic lymphoma kinase) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer [published online ahead of print January 26, 2012]. Cancer. doi:10.1002/cncr. 27411.
-
Cancer
, vol.26
, pp. 2012
-
-
Camidge, D.R.1
Theodoro, M.2
Maxson, D.A.3
-
20
-
-
79951994379
-
Comparison of crizotinib (PF-02341066) pharmacokinetics between Asian and non-Asian patients with advanced malignancies
-
Ou SHI, Salgia R, Clark J. Comparison of crizotinib (PF-02341066) pharmacokinetics between Asian and non-Asian patients with advanced malignancies. J Thorac Oncol. 2010;5(suppl. 5):S382.
-
(2010)
J Thorac Oncol
, vol.5
, Issue.SUPPL. 5
-
-
Ou, S.H.I.1
Salgia, R.2
Clark, J.3
-
21
-
-
80054728915
-
Phase 2 data for crizotinib (PF-02341066) in ALK-positive advanced non-small cell lung cancer (NSCLC): PROFILE 1005 [abstract 1618]
-
Riely G, Kim D-W, Crinò L, et al. Phase 2 data for crizotinib (PF-02341066) in ALK-positive advanced non-small cell lung cancer (NSCLC): PROFILE 1005 [abstract 1618]. J Thorac Oncol. 2011;6(suppl 2):411s.
-
(2011)
J Thorac Oncol
, vol.6
, Issue.SUPPL.. 2
-
-
Riely, G.1
Kim, D.-W.2
Crinò, L.3
-
22
-
-
80053386829
-
Effect of crizotinib on overall survival in advanced NSCLC harboring anaplastic lymphoma kinase gene rearrangement: A retrospective analysis
-
Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in advanced NSCLC harboring anaplastic lymphoma kinase gene rearrangement: a retrospective analysis. Lancet Oncol. 2011;11:1004-1012.
-
(2011)
Lancet Oncol
, vol.11
, pp. 1004-1012
-
-
Shaw, A.T.1
Yeap, B.Y.2
Solomon, B.J.3
-
23
-
-
84859507778
-
Preliminary characterization of visual events reported by patients receiving crizotinib for the treatment of advanced ALK-positive non-small cell lung cancer
-
Poster Presented At, Stockholm, Sweden. Abstract 3030., September
-
Solomon B, Chiappori A, Lamb A, et al. Preliminary characterization of visual events reported by patients receiving crizotinib for the treatment of advanced ALK-positive non-small cell lung cancer. Poster presented at: European Multidisciplinary Cancer Congress; September 23-27, 2011; Stockholm, Sweden. Abstract 3030.
-
(2011)
European Multidisciplinary Cancer Congress
, pp. 23-27
-
-
Solomon, B.1
Chiappori, A.2
Lamb, A.3
-
24
-
-
84859507780
-
PROFILE 1005: Preliminary patient-reported outcomes (PROs), from an ongoing phase 2 study of crizotinib (PF-02341066) in anaplastic lymphoma kinase (ALK)-positive advanced nonsmall cell lung cancer (NSCLC)
-
Oral presentation at, Amsterdam, The Netherlands., July
-
Blackhall FH, Petersen JA, Wilner K, et al. PROFILE 1005: preliminary patient-reported outcomes (PROs) from an ongoing phase 2 study of crizotinib (PF-02341066) in anaplastic lymphoma kinase (ALK)-positive advanced nonsmall cell lung cancer (NSCLC). Oral presentation at: 14th World Conference on Lung Cancer (WCLC); July 3-7, 2011; Amsterdam, The Netherlands.
-
(2011)
14th World Conference on Lung Cancer (WCLC)
, pp. 3-7
-
-
Blackhall, F.H.1
Petersen, J.A.2
Wilner, K.3
-
25
-
-
84869451039
-
A global phase 2 study including efficacy, safety and patient-reported outcomes (PROs) with crizotinib in patients (Pts) with ALK-positive non-small cell lung cancer (NSCLC) [abstract]
-
Kim DW, Blackhall F, Soria JC, et al. A global phase 2 study including efficacy, safety and patient-reported outcomes (PROs) with crizotinib in patients (Pts) with ALK-positive non-small cell lung cancer (NSCLC) [abstract]. Eur J Cancer. 2011;47(suppl):S617.
-
(2011)
Eur J Cancer
, vol.47
, Issue.SUPPL..
-
-
Kim, D.W.1
Blackhall, F.2
Soria, J.C.3
-
26
-
-
81355124049
-
Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen
-
Zhang S, Wang F, Keats J, et al. Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem Biol Drug Des. 2011;78(6):999-1005.
-
(2011)
Chem Biol Drug Des
, vol.78
, Issue.6
, pp. 999-1005
-
-
Zhang, S.1
Wang, F.2
Keats, J.3
-
27
-
-
80052793410
-
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors
-
Sasaki T, Koivunen J, Ogino A, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 2011; 71(18):6051-6060.
-
(2011)
Cancer Res
, vol.71
, Issue.18
, pp. 6051-6060
-
-
Sasaki, T.1
Koivunen, J.2
Ogino, A.3
-
28
-
-
78049426513
-
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors
-
Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med. 2010;363(18):1734-1739.
-
(2010)
N Engl J Med
, vol.363
, Issue.18
, pp. 1734-1739
-
-
Choi, Y.L.1
Soda, M.2
Yamashita, Y.3
-
29
-
-
84856999699
-
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers
-
Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med. 2012;4(120):120ra17.
-
(2012)
Sci Transl Med
, vol.4
, Issue.120
-
-
Katayama, R.1
Shaw, A.T.2
Khan, T.M.3
|